Table 3 Summary of the current literature on CHD1L deregulation in solid cancers
From: Diversity roles of CHD1L in normal cell function and tumorigenesis
| Cancer | Deregulation | Downstream targets | Phenotypic effect | clinical impact | References |
|---|---|---|---|---|---|
| HCC | CHD1L↑ | P53↓, p21↓, cyclinE↑, CDK2↑ | G1/S phase transition↑, apoptosis↓, proliferation↑ | [1] | |
| CHD1L↑ | Nur77↓ | apoptosis↓ | [18] | ||
| CHD1L↑ | ARHGEF9↑, Cdc42↑ | migration↑, invasion↑, metastasis↑ | [14] | ||
| CHD1L↑ | TCTP↑, Cdc25c↓, Cdk1↓ | Mitotic progression↑, aneuploidy↑ | [15] | ||
| CHD1L↑ | SPOCK1↑, Akt↑ | apoptosis↓, invasion↑, metastasis↑ | [16] | ||
| CHD1L↑ | NTKL↑ | cell growth↑, colony formation↑, G1/S transition↑ | [17] | ||
| CHD1L↑ | NA | Poor Prognosis | [21] | ||
| Ovarian carcinoma | CHD1L↑ | NA | metastasis↑ | Prognostic biomarker | [23] |
| CHD1L↑ | METAP2↑ | invasion↑, metastasis↑ | [19] | ||
| Gastric cancer | CHD1L↑ | NA | Prognostic biomarker | [22] | |
| Colorectal carcinoma | CHD1L↑ | NA | G1/S phase transition↑, apoptosis↓ | Prognostic biomarker | [24] |
| Bladder cancer | CHD1L↑ | NA | Prognostic biomarker | [25] | |
| Breast cancer | CHD1L↑ | NA | Prognostic biomarker | [27] | |
| CHD1L↑ | MDM2↑, p53↓ | Cell cycle↑, cell motility↑ | [63] | ||
| CHD1L↑ | PI3K↑, Akt↑, ARK5↑, mTOR↑, MMP2↑, MMP9↑ | chemotaxis↑, invasion↑, lung colonization↑ | [4] | ||
| Nasopharyageal carcinoma | CHD1L↑ | NA | Prognostic biomarker | [27] | |
| Glioma | CHD1L↑ | PCNA↑, β-catenin ↓, cyclinD1↑, p53↓, p21↓, cyclinE↑, Cdk2↑, c-capase3↓, Bcl2↑ | G1/S phase transition↑, proliferation↑, apoptosis↓, migration↑, invasion↑ | [64] | |
| NSCLC | CHD1L↑ | NA | Prognostic biomarker | [12] | |
| CHD1L↑ | ABCB1↑, c-Jun↑, NF-kB↑ | Cisplatin resistance | [66] | ||
| Myeloma | CHD1L↑ | c-capase9↓, capase3↓ | Anti-apoptosis, cell adhesion-mediated drug resistance↑ | [6] | |
| Pancreatic cancer | CHD1L↑ | β-catenin↑ | Cell proliferation↑ | Poor prognosis | [65] |
| Esophageal carcinoma | CHD1L↑ | NA | proliferation↑, apoptosis↓, metastasis↑, invasion↑ | Poor prognosis | [28] |
| CHD1L↑ | PI3K/Akt pathway↑ | viability↑, apoptosis↓, cisplatin cytotoxicity↓, glycolysis↑ | [67] | ||
| Cholangiocarcinoma | CHD1L↑ | hMLH1↓ | Prognostic biomarker | [103] | |
| CHD1L↑ | P53↓, cyclinD1↑, CDK2↑, E-cadherin↓, N-cadherin↑, Vimentin↑ | EMT↑, G1/S transition↑, Cell proliferation↑ | Poor prognosis | [20] |